Despite the substantial disease burden from gout in Singapore — with a majority of the patients not being at the serum urate (SU) target, only two-thirds of the patients receive urate-lowering therapy (ULT), according to a local study.
The incidence of osteoporotic fractures is expected to grow by more than 50 percent, according to a recent Singapore study. This will be accompanied by a spike in economic burden, both directly and indirectly associated with healthcare.
The novel oral pan-Janus kinase (JAK) inhibitor peficitinib showed superior efficacy and safety over placebo in patients with rheumatoid arthritis (RA) who have insufficient response to prior disease-modifying antirheumatic drugs (DMARDs) and methotrexate, the phase III RAJ3 and 4 trials show.
Targeted antibiotic therapy for 2 weeks following initial surgical lavage for septic arthritis – particularly of the hand and wrist – is noninferior to the currently recommended 4-week duration for inducing remission, a study has shown.
New drug applications approved by US FDA as of 01 - 15 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 16 - 30 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Both the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) are reliable methods of determining disease activity in Singaporeans with axial spondyloarthritis (axSpA), according to a recent study.
The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.